Google NewsFirebrick Pharma (ASX:FRE) Gains 14.29% as Nasodine Commercial Expansion Stays in View - Kalkine
Firebrick Pharma (ASX:FRE) Gains 14.29% as Nasodine Commercial Expansion Stays in View Kalkine
Firebrick Pharma (FRE) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXUpdate - Notification regarding unquoted securities - FRE
other announcement
ASX Biotech Stock Firebrick Pharma (ASX: FRE) Advances on Product Development Momentum - Kalkine
ASX Biotech Stock Firebrick Pharma (ASX: FRE) Advances on Product Development Momentum Kalkine
Nasodine Composition Patent Granted in New Zealand
other announcement
Change of Director's Interest Notice - Peter Molloy
director_dealing announcement
Change of Director's Interest Notice - Stephen Goodall
director_dealing announcement
March 2026 Quarterly Activity Report & Appendix 4C
other announcement
Notification regarding unquoted securities - FRE
other announcement
Notification regarding unquoted securities - FRE
other announcement
Notification regarding unquoted securities - FRE
other announcement
Firebrick Secures $1.5 million via Placement
capital_raise announcement
Registration Agreement and Approval of Nasodine in Indonesia
other announcement
Firebrick to present at NWR Virtual Healthcare Conference
other announcement
FRE appoints Head of Business Development and Licensing
other announcement
Initial Director's Interest Notice - Al Moghaddam
other announcement
Appendix 4D & Half-Year Financial Report to 31 December 2025
other announcement
Notification regarding unquoted securities - FRE
other announcement
December 2025 Quarterly Activity Report & Appendix 4C
other announcement
Nasodine Throat Spray Product Launch in Singapore
other announcement